From Global Products to Individual Functionings: Medicinal Drugs in Developing Countries



Previous chapters and indeed most of the existing literature on the welfare effects of new products in developing countries are based on a form of analysis (developed primarily by Lancaster) that focuses on the specific characteristics embodied in those products.1 Those combinations of characteristics are then evaluated from the point of view of their appropriateness to household groups differentiated, most frequently, by levels of income. Because they are mainly produced in developed countries, new products, so the argument usually runs, contain a high proportion of ‘high-income’ characteristics that make them unconducive to the satisfaction of basic needs in developing countries. Or, put another way, the conclusion is typically that new products tend to confer their benefits disproportionately on rich rather than poor consumers in developing countries.


Drug Product Drug Consumption Welfare Effect Global Product Health Functionings 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. K. Bennett, P. Tugwell, D. Sackett and B. Haynes (1990). ‘Relative Risks, Benefits, and Costs of Intervention’, in K. Warren and A. Mahmoud (eds), Tropical and Geographical Medicine, 2nd edn, McGraw-Hill.Google Scholar
  2. R. Blum (1981). ‘Factors Affecting Individual Use of Medicines’, in R. Blum et al. (eds), Pharmaceuticals and Health Policy, Holmes and Meier.Google Scholar
  3. G. A. Cohen (1993). ‘Equality of What? On Welfare, Goods and Capabilities’ in M. Nussbaum and A. Sen (eds), The Quality of Life, Clarendon Press.Google Scholar
  4. G. Cowan and B. Heap (1993). Clinical Tropical Medicine, Chapman and Hall.Google Scholar
  5. T. Greenhalgh (1987). ‘Drug Prescription and Self-Medication in India: An Exploratory Survey’, Social Science Medicine, 25 (3).Google Scholar
  6. A. Hardon (1987). ‘The Use of Modern Pharmaceuticals in a Filipino Village: Doctor’s Prescription and Self Medication’, Social Science Medicine, 25 (3).Google Scholar
  7. G. Helleiner (1975). ‘The Role of Multinational Corporations in the LDC’s Trade in Technology’, World Development, 3 (4).Google Scholar
  8. H. Hogerzeil (1986). ‘Use of Essential Drugs in Rural Ghana’, International Journal of Health Services, 16 (3).Google Scholar
  9. J. James and F. Stewart (1981). ‘New Products: A Discussion of the Welfare Effects of the Introduction of New Products in Developing Countries’, Oxford Economic Papers.Google Scholar
  10. D. Jelliffe and E. Jelliffe (1978). Human Milk in the Modern World, Oxford University Press.Google Scholar
  11. R. Jenkins (1988). ‘Transnational Corporations and Third World Consumption: Implications of Competitive Strategies’, World Development, 16 (11).Google Scholar
  12. K. Krishnaswamy, B. Kumar and G. Radhaiah (1985). ‘A Drug Survey-Precepts and Practices’, European Journal of Clinical Pharmacology, 29.Google Scholar
  13. E. Martin (1978). Hazards of Medication, 2nd edn, J. B. Lippincott Co.Google Scholar
  14. M. Muller (1982). The Health of Nations, Faber and Faber.Google Scholar
  15. N. Osifo (1983). ‘Overpromotion of Drugs in International Product Package Inserts’, Tropical Doctor, Jan.Google Scholar
  16. H. Rang, M. Dale and J. Ritter (1995). Pharmacology, Churchill, Livingstone.Google Scholar
  17. A. Schapira (1990). ‘The Resistance of Falciparum Malaria in Africa to 4-Aminoquinolines and Antifolates’, Scandinavian Journal of Infectious Diseases, Supplement 75.Google Scholar
  18. K. Schmidt (1995). ‘Inbred Parasites May Spur Resistance’, Science, 269, 22 Sept.Google Scholar
  19. C. Sekhar, R. Raina and G. Pillai (1981). ‘Some Aspects of Drug Use in Ethiopia’, Tropical Doctor, July.Google Scholar
  20. A. Sen (1985). Commodities and Capabilities, North-Holland.Google Scholar
  21. M. Silverman and P. Lee (1974). Pills, Profits and Politics, University of California Press.Google Scholar
  22. M. Silverman, P. Lee and M. Lydecker (1982). Prescriptions for Death: the Drugging of the Third World, University of California Press.Google Scholar
  23. R. Snyder, H. Mofenson and J. Greensher (1973). ‘Toxicity from Lomotil’, Clinical Pediatrics, January.Google Scholar
  24. F. Stewart (1977). Technology and Underdevelopment, Macmillan.CrossRefGoogle Scholar
  25. D. Weatherall (1990). ‘Common Genetic Disorders in the Tropics’, in K. Warren and A. Mahmoud (eds), Tropical and Geographical Medicine, 2nd edn, McGraw-Hill.Google Scholar
  26. I. Wickramasekera (1985). ‘A Conditional Response Model of the Placebo Effect: Predictions from the Model’ in L. White, B. Tursky and G. Schwartz (eds), Placebo: Theory, Research and Mechanisms, Guilford Press.Google Scholar
  27. I. Wolffers (1987). ‘Drug Information and Sale Practices in Some Pharmacies of Colombo, Sri Lanka’, Social Science Medicine, 25 (3).Google Scholar

Copyright information

© Jeffrey James 2000

Authors and Affiliations

  1. 1.Tilburg UniversityThe Netherlands

Personalised recommendations